WHilst officially the TGA will say they won't consider it, they will be aware of the FDA CelGro Dental study that was successful. TGA is in the bag in my opinion. 2021 we should have CelGro dental commercially avaiable across US, Europe and Australia. OCC almost has too many things going on. Applications across the three aspects of CelGro and the ACL rope (we haven't even discussed the Utrine mesh potential), ATI submissions and trials and then quietly ACI, which had been on the back burner.
I don't know where the stock price goes in the short-term, but long term this companies procedures/products have huge potential.
Ann: CelGro Nerve Repair AUS Regulatory Application Submitted, page-53
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.005(1.35%) |
Mkt cap ! $76.49M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.5¢ | $52.06K | 142.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20235 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 4244 | 1 |
View Market Depth
| Last trade - 14.42pm 20/08/2024 (20 minute delay) ? |
| OCC (ASX) Chart |